Alentis appoints Alberto Toso Chief Scientific Officer
        
         
        
        
          
          
          
           
        
        
      
        
     
        
        Basel, Switzerland – 29 April, 2024, Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today…
andy06.05.2024








